Supplements to European Urology are published under the title European Urology Supplements (ISSN 1569-9056). All subscribers to European Urology automatically receive this publication.
European Urology Supplements is the perfect publication vehicle for the proceedings of a scientific symposium, commissioned thematic issues, or for disseminating a selection of invited articles.
What makes European Urology Supplements unique is the fact that it has impact factor of 3.121 (2018) and sits within the widely respected European Urology family of urology publications published by Elsevier on behalf of the EAU and EBU. This journal also incorporates the EAU-EBU Update Series (ISSN 1871-2592).You can also visit:
European Urology (ISSN 0302-2838) and European Urology Focus (ISSN 2405-4569).
Each month European Urology publishes a wide variety of articles in all areas of urology and related sciences. European Urology Supplements is a separate publication aimed at the same readership and is sent to all European Urology subscribers. The guidelines below are based on those for European Urology and have been adapted to the specific aspects of the supplements.European Urology Supplements publishes proceedings of meetings, symposia and monographs. The publications require sponsorship. All material for a supplement must go first to the Editor-in-Chief.
Submissions of the individual articles should be made through the Web site of our online submission system EES (https://ees.elsevier.com/eursup).Editorial Office Contact Information
Questions regarding manuscript submission may be sent to:
European Urology Editorial Office
Ms. Cathy Pierce, Editorial Office Manager
Statements in articles or opinions expressed by any contributor in any article are not the responsibility of the editors or the publishers. The publisher is not responsible for the loss of manuscripts through circumstances beyond its control.Accepted manuscripts will be copy-edited to bring them into conformity with the journal's style. The final version of the manuscript following copy-editing will be sent back to the author only if specific queries need to be clarified.
It is the author's responsibility to obtain permission to reproduce any parts of other publications (i.e., tables, figures). Precise reference to the original work must be given in the legends.Authors are encouraged to submit figures for the front cover of the journal.
Editorial PolicyAuthorship Criteria
The corresponding author must take responsibility for the integrity of the work as a whole, from inception to published article. Each collaborating author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Authorship credit should be based on: substantial contributions to conception and design, acquisition of data, analysis and interpretation of data, drafting of the article or revising it critically for important intellectual content, statistical analysis, obtaining funding, administrative, technical or material support, supervision and any other specifics to be declared at publication.Role of the Corresponding Author
The corresponding author will serve on behalf of all co-authors as the primary correspondent with the editorial office during the submission and review process. If the manuscript is accepted, the corresponding author will review an edited typescript and proof and will be identified as the corresponding author in the published article. The corresponding author is responsible for ensuring that all information included in the Conflict of Interest Policy form is complete and has been agreed on by all authors. ''Acknowledgment'' is the general term for the list of contributions, credits, and other information included at the end of the text of a manuscript before the references.Group Authorship
If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship as described above. If that is not the case, a group must designate one or more individuals as authors or members of a writing group who meet full authorship criteria and requirements. Other group members who are not authors may be listed in an Acknowledgment.Conflicts of Interest and Financial Disclosures
Completion of the European Urology Supplements Conflict of Interest Policy form is an obligatory step of the submission process.
The corresponding author must collect the relevant information for the Conflict of Interest statements from all co-authors, if any, and submit these via EES together with the manuscript. If the completed form is not submitted with the manuscript, the manuscript will not be considered for peer review. Download this form here: form.
Authors are expected to provide detailed information about all relevant financial interests and relationships or financial conflicts (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), particularly those present at the time the research was conducted and through publication, as well as other financial interests (such as patent applications in preparation), that represent potential future financial gain.For example, authors of a manuscript about prostate cancer should report all financial relationships they have with all manufacturers of products used in the management of prostate cancer, not only those relationships with companies whose specific products are mentioned in the manuscript.
Although many universities and other institutions have established policies and thresholds for reporting financial interests and other conflicts of interest, European Urology requires complete disclosure of all relevant financial relationships and potential financial conflicts of interest, regardless of amount or value.All disclosures of any potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript will be disclosed by the corresponding author on behalf of each co-author, if any, as part of the submission process. Likewise, authors without conflicts of interest, will be requested to state so as part of the submission process.
If authors are uncertain about what constitutes a relevant financial interest or relationship, they should contact the editorial office.Failure to include this information in the Conflict of Interest Policy form will prohibit commencement of the review process of the manuscript.
For all accepted manuscripts, each author's disclosures of conflicts of interest and relevant financial interests and affiliations and declarations of no such interests will be published.The policy requesting disclosure of conflicts of interest applies for all manuscript submissions. If an author's disclosure of potential conflicts of interest is determined to be inaccurate or incomplete after publication, a correction will be published to rectify the original published disclosure statement.
Authors are also required to report detailed information regarding all financial and material support for the research and work, including but not limited to grant support, funding sources, and provision of equipment and supplies as part of the submission process. For all accepted manuscripts, each author's source of funding will be published.Funding/Support and Role of Sponsor
All financial and material support for the research and work will be requested to be clearly and completely identified as part of the submission process. The specific role of the funding organization or sponsor in each of the following should be specified: ''design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.'' The corresponding author is responsible for acknowledging this on the Conflict of Interest Policy form to be sent to the European Urology Supplements contact persons at Elsevier at the time of submission.Data Access and Responsibility
For all reports (regardless of funding source) containing original data, at least one named author (e.g., the principal investigator) who is independent of any commercial funder should indicate that she or he ''had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.'' This exact statement will be requested as part of the submission process. Modified statements or generic statements indicating that all authors had such access are not acceptable.Duplicate/Previous Publication or Submission
Manuscripts are considered with the understanding that they have not been published previously in print or electronic format and are not under consideration by another publication or electronic medium. Copies of related or possibly duplicative materials (ie, those containing substantially similar content or using the same or similar data) that have been previously published or are under consideration elsewhere must be provided at the time of manuscript submission.Ethical Approval of Studies and Informed Consent
For human or animal experimental investigations, formal review and approval, or review and waiver, by an appropriate institutional review board or ethics committee is required and should be described in the Methods section. For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. For investigations of human subjects, state in the Methods section the manner in which informed consent was obtained from the study participants (ie, oral or written).Personal Communications and Unpublished Data
A signed statement of permission should be included from each individual identified as a source of information in a personal communication or as a source for unpublished data, and the date of communication and whether the communication was written or oral should be specified.Previous Presentation or Release of Information
A complete report following presentation at a meeting or publication of preliminary findings elsewhere (e.g., an abstract) is eligible for consideration for publication.Unauthorized Use
Published manuscripts become the permanent property of the EAU and may not be published elsewhere in whole or in part without written permission. Unauthorized use of the European Urology name, logo, or any content for commercial purposes or to promote commercial goods and services (in any format, including print, video, audio, and digital) is not permitted by the EAU.Editorial Review and Publication
The peer review process is carefully supervised by the editors of the journal. Manuscripts will be considered initially by the editors to assess whether they reach a priority score justifying peer review. Manuscripts considered of interest by the editors will be reviewed by internationally recognized experts on the subject. When necessary, a biostatistician will also review manuscripts. Reviewers are allotted 14 days to complete their reviews. The reviewers will not be blinded to the names of the authors or the institution from which the manuscripts have been sent. Authors will be asked to incorporate the requested changes for the revision in 5 working days. The final decision to accept or reject a manuscript will be made by the Editor-in-Chief in conjunction with the Associate Editors.Types of Articles
Original articlesThese manuscripts typically report on basic and translational research, epidemiology, pathophysiology, diagnosis, medical or surgical treatment, and minimally invasive therapy related to urologic diseases.
Each manuscript should clearly state an objective or hypothesis; the design and methods (including the study setting and dates, patients or participants with inclusion and exclusion criteria and/or participation or response rates, or data sources, and how these were selected for the study); the essential features of any interventions; the main outcome measures; the main results of the study; a discussion section placing the results in context with the published literature and addressing study limitations; and the conclusions. Data included in research reports should be as timely and current as possible.The format of the original article should be as follows
AbstractProvide a structured abstract no longer than 300 words with the following sections: Background; Objective; Design, Setting, and Participants; Intervention(s) (if applicable); Measurements; Results and Limitations; Conclusions.
For brevity, parts of the abstract may be written as phrases rather than complete sentences. Each section should include the following content (see abstract structure details below):
- Background: The abstract should begin with a sentence or two explaining the clinical (or other) importance of the study question.
- Objective: State the precise objective or study question addressed in the manuscript (e.g., ''To determine whether. . .''). If more than one objective is addressed, the main objective should be indicated and only key secondary objectives stated.
- Design, Setting, and Participants: Describe the basic design of the study. State the years of the study and the duration of follow-up. Describe the study setting to assist readers to determine the applicability of the report to other circumstances, for example, general community, a primary care or referral center, private or institutional practice, or ambulatory or hospitalized care. State the clinical disorders, important eligibility criteria, and key sociodemographic features of patients. The numbers of participants and how they were selected should be provided. In follow-up studies, the proportion of participants who completed the study must be indicated. In intervention studies, the number of patients withdrawn because of adverse effects should be given. For selection procedures, these terms should be used, if appropriate: random sample (where random refers to a formal, randomized selection in which all eligible individuals have a fixed and usually equal chance of selection); population-based sample; referred sample; consecutive sample; volunteer sample; convenience sample.
- Intervention(s) (if applicable): The essential features of any interventions (surgical or medical) should be described. The nonproprietary drug or device names should be used unless the specific trade name is essential to the study.
- Measurements: Indicate the primary and secondary study outcome measurement(s).
- Results and Limitations: The main outcomes of the study should be reported and quantified. Complications or sequelae of the interventions used must be detailed. Particular attention must be given to statistical analysis. All randomized controlled trials should include the results of intention-to-treat analysis, and all surveys should include response rates. Limitations of the study should be acknowledged.
- Conclusions: Provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization. Indicate whether additional study is required before the information should be used in usual clinical settings. Give equal emphasis to positive and negative findings of equal scientific merit.
- Trial Registration: For clinical trials, the name of the trial registry, registration number, and URL of the registry must be included.
- Number of references should be limited to 30.
- Maximum word count is 3000, including the abstract but not including the references, tables, figures, or legends. Should the word count exceed this limit, please consult with the Editorial Office.
Two or three sentences (no more than 40 words) summarizing the main message expressed in the article must be uploaded as a separate file.Ethical Considerations and Registration of Clinical Trials
Trial Registration: As a member of the International Committee of Medical Journal Editors (ICMJE), European Urology requires, as a condition of consideration for publication, registration of all trials in a public trials registry that is acceptable to the ICMJE and that requires the minimum registration data set as described by the ICMJE.Acceptable trial registries include the following:http://www.actr.org.au
For this purpose, a clinical trial is any study that prospectively assigns human subjects to intervention or comparison groups to evaluate the cause and- effect relationship between a medical/surgical intervention and a health outcome. All clinical trials, regardless of when they were completed, and secondary analyses of original clinical trials must be registered before submission of a manuscript based on the trial. For clinical trials starting patient enrollment after July 2005, trials must be registered before onset of enrollment. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt. Trial registry name, registration identification number, and the URL for the registry should be included at the end of abstract.CONSORT Flow Diagram and Checklist: Manuscripts reporting the results of randomized controlled trials should include the CONSORT flow diagram showing the progress of patients throughout the trial. The CONSORT checklist also should be completed and submitted with the manuscript and can be found on http://www.europeanurology.com .
Review ArticlesThese are reviews that systematically find, select, critique, and synthesize evidence relevant to well defined questions about diagnosis, therapy, and prognosis. The format of the review article should be as follows:
AbstractProvide a structured abstract no longer than 300 words with the following sections: Context, Objective, Evidence Acquisition, Evidence Synthesis, Conclusion (see abstract structure details below.)
- Context: Include one or two sentences describing the clinical question or issue and its importance in clinical practice or public health.
- Objective: State the precise primary objective of the review. Indicate whether the review emphasizes factors such as cause, diagnosis, prognosis, therapy, or prevention and include information about the specific population, intervention, exposure, and tests or outcomes that are being reviewed.
- Evidence Acquisition: Describe the data sources used, including the search strategies, years searched, and other sources of material, such as subsequent reference searches of retrieved articles. Methods used for quality assessment and inclusion of identified articles should be explained.
- Evidence Synthesis: The major findings of the review of the clinical issue or topic should be addressed in an evidence-based, objective, and balanced fashion, with the highest quality evidence available receiving the greatest emphasis.
- Conclusions: The conclusions should clearly answer the questions posed if applicable, be based on available evidence, and emphasize how clinicians should apply current knowledge.
The text of the manuscript should be divided as follows: Introduction, Evidence Acquisition, Evidence Synthesis, Conclusions.
- Maximum word count is 4000, including the abstract but not including the references, tables, figures, or legends. Should the word count exceed this limit, please consult with the Editorial Office.
- Number of references should be limited to 50.
EU-ACME articlesSelected articles per issue will be designated by the Editor-in-Chief at the time of final acceptance as EU-ACME articles. The authors will be asked to provide six EU-ACME questions for these articles based on the information provided in the article. Four possible answers should be provided for each question, with only one of them being the correct one. The correct answer should be explained in text limited to 50 words; up to three references are allowed to support this explanation. (Specifically dedicated instructions for authors for these questions and answers will be provided.) The questions and answers will not be printed in the journal but will be available at http://acme.uroweb.org/europeanurology/
Manuscript Preparation and Submission RequirementsManuscript Submission
Original manuscripts written in English should be submitted through the web site of our online submission system EES (https://ees.elsevier.com/eursup/), in Word or LaTeX format for text and EPS or TIFF for illustrations. Authors may also check the status of submitted articles at this site. At the time of submission, complete contact information (postal/mail address, e-mail address, telephone and fax numbers) for the corresponding author is required. First and last names, e-mail addresses, and institutional affiliations of all co-authors are also required. Manuscripts submitted through the online system should not also be submitted by mail or e-mail. Once the manuscript is submitted online, the corresponding author will receive a manuscript number and will be able to follow the status of the manuscript through the online system.Manuscript Components
Include a title page, abstract, text, references, and as appropriate, figure legends, tables, and figures, take home message (for original and review articles). Start each of these sections on a new page, numbered consecutively, beginning with the title page. Please check the instructions per article type listed above.Manuscript File Formats
For submission and review, acceptable manuscript file formats include Word, WordPerfect, EPS, Text, Postscript, or RTF format. Use 12-point font size, double-space text, and leave right margins unjustified with margins of at least 2.5 cm. Each page should be numbered in the upper right corner, beginning on p. 2. Add continuous line numbering.Title Page
The title page should include a word count for the text and abstract separately. Authors' full names, highest academic degrees, and affiliations should also be included (see list below). If an author s affiliation has changed since the work was done, the new affiliation also should be listed. For indexing purposes, 3—10 key words should be supplied in alphabetical order (see example below)
- Authors (first name and initials followed by surname, e.g., Juan X. Alvarez)
- Affiliations (if multiple affiliations are listed, indicate with lowercase letter footnotes following the respective authors names)
- Contact information for corresponding author, including full mailing address, telephone number, fax number, and e-mail address
- For indexing purposes, 3—10 keywords should be supplied (in alphabetical order) as follows: Keywords Benign prostatic hyperplasia; Doxazosin; Lower urinary tract symptoms
- Word count of text: include the abstract but not the references in this count
- Word count of the abstract (please remember Abstracts cannot exceed 300 words)
HeadingsDo not use automatically generated numbering or bulleting systems or hidden text (e.g., for headings, references, footnotes, lists).
Units of MeasurementUnits of measurements must conform to the Système International (SI): year(s), yr; month(s), mo; days, d; hours, h; minutes, min; seconds, s; grams, g; liters, l; meters, m; sample size, n; degrees of freedom, df; standard error of the mean, SE; standard deviation, SD; probability, p.
Numerals and AbbreviationsUse numerals for all values greater than ten and those followed by a unit; otherwise, spell out (e.g., 18 patients, 0.8 g/ml, 47%, 37 8C, six cases). Spell out numbers at the beginning of a sentence. Abbreviations must be defined at first use in each of the following: text, tables, and figure legends.
Conflict of Interest statementsThe European Urology Supplements Conflict of Interest Policy form needs to be completed and uploaded together with the submission of the manuscript. The Conflict of Interest statements will be inserted by the copy-editor at the end of the article, before the references.
AcknowledgmentsThe Acknowledgments section is the general term for the list of contributions, credits, and other information included at the end of the text of a manuscript but before the references. Authors should obtain written permission to include the names of individuals in the Acknowledgment section.
ReferencesIn the text, references should be cited in numerical order, with citation numbers placed in square brackets.
Personal communications (pers. comm.) and unpublished data (unpubl. data) are mentioned only in the text: (pers. comm., A. Brown, Ithaca, New York, USA).Each reference number should correspond to a single published source.
List all authors up to six; for more than six authors list the first three followed by et al.Use Index Medicus abbreviations for journals. Provide full page ranges, using the abbreviated format shown below.
 MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects. Spinal Cord 2007;45:535—41.
 Filocamo M, Li Marzi V, Del Popolo G, et al. Pharmacologic treatment in postprostatectomy stress urinary incontinence. Eur Urol 2007;51:1559—64.
 Hatzimouratidis K, Hatzichristou D. Testosterone and erectile function: an unresolved enigma. Eur Urol 2007;52:26—8.
 King RC, Stansfield WD. A dictionary of genetics, ed. 3. New York: Oxford University Press; 2002.
 Hunskaar S, Burgio K, Diokno AC, Herzog AR, Hjalmas K, Lapitan MC. Epidemiology and natural history of urinary incontinence. In: Abrams P, Cardoza L, Khoury S, Wein A, editors. Incontinence: 2nd International Consultation on Incontinence, ed. 2. Plymouth, UK: Health Publications, 2002. p. 165—201.
 Kato H. Neuroendocrine cells: their effect on the development of benign prostatic hyperplasia. Ph.D. diss. [MS thesis], University of Tokyo Medical School, Tokyo, 1997.
Data referencesThis journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. This identifier will not appear in your published article.
An example of how such a reference should look: Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. http://dx.doi.org/10.17632/xwj98nb39r.1.
- Compose tables in a word-processing program; do not insert as graphic elements. Number tables with Arabic numerals in the order they appear in the text. Place each table on a separate page.
- Provide a title at the top of each table.
- Explain abbreviations and include any other comments in a note at the bottom of each table.
- Figures must supplement, not duplicate, the tables and text.
- Illustrations must clearly convey their message and be of high quality and sufficient size and clarity (especially lettering, arrows, and data points) to be interpretable when reduced for publication.
- Number figures with Arabic numerals in the order they appear in the text.
- Provide a separate list of figure legends at the end of the text; do not place legends on the figures.
- Do not embed artwork within the text; figures should be supplied as separate files.
- Guidelines for submitting figures in an electronic format can be found at https://www.elsevier.com/artwork.
ProofsUnless otherwise indicated, proofs are sent in PDF format via e-mail to the central contact person responsible for coordinating the checking of the proofs. Proofs must be returned within the deadline specified by the Publisher.
Proofs can be accompanied by separate queries. Authors should not contact the editorial office of the journal with regard to these queries. All queries must be answered directly on the page proofs. If corrections are not made and returned to Elsevier by the specified deadline, the article will be published as is.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.